Microbot Medical announced the appointment of Dr. Juan Diaz-Cartelle as its new Chief Medical Officer, effective December 1, 2023. The hiring of Dr. Diaz-Cartelle, a U.S.-based physician, coincides with the transition of the Company focusing mainly on research and development in Israel to the Company increasing its U.S.-based activities, which includes its planned clinical trials for the LIBERTY Endovascular Robotic Surgical System in the U.S., the regulatory process with the FDA and establishing the commercial foundations to enter the U.S market. of experience in the endovascular and interventional space, along with an impressive track record in clinical research. Before joining the Company, Dr. Diaz-Cartelle served for 14 years as the Senior Medical Director for the Peripheral Interventional Division at Boston Scientific Corporation. Dr. Diaz-Cartelle succeeds Dr. Eyal Morag, the Company’s previous CMO.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See the top stocks recommended by analysts >>
Read More on MBOT:
- Microbot Medical Appoints Seasoned Medical Expert Dr. Juan Diaz- Cartelle as its New Chief Medical Officer in Anticipation of Its Clinical, Regulatory and Commercial Activities
- Microbot Medical files $75M mixed securities shelf
- Microbot Medical completes EMC testing section of V&V process
- Microbot Medical Successfully Completed Integral Part of the Verification and Validation Process
- Microbot Medical Granted Registered Trademark from The U.S. Patent and Trademark Office
